<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">medsovet</journal-id><journal-title-group><journal-title xml:lang="ru">Медицинский Совет</journal-title><trans-title-group xml:lang="en"><trans-title>Meditsinskiy sovet = Medical Council</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2079-701X</issn><issn pub-type="epub">2658-5790</issn><publisher><publisher-name>REMEDIUM GROUP Ltd.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.21518/2079-701X-2017-18-61-64</article-id><article-id custom-type="elpub" pub-id-type="custom">medsovet-2033</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Бронхиальная астма</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>Bronchial asthma</subject></subj-group></article-categories><title-group><article-title>ЧТО ВАЖНО ЗНАТЬ, ЧТОБЫ ДОБИТЬСЯ КОНТРОЛЯ НАД АСТМОЙ?</article-title><trans-title-group xml:lang="en"><trans-title>WHAT IT’S IMPORTANT TO KNOW TO CONTROL ASTHMA?</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Мещерякова</surname><given-names>Н. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Mescheryakova</surname><given-names>N. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>к.м.н.</p></bio><bio xml:lang="en"><p>PhD in medicine</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Российский научный исследовательский медицинский университет им. Н.И. Пирогова</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Pirogov Russian Scientific and Research Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2017</year></pub-date><pub-date pub-type="epub"><day>03</day><month>11</month><year>2017</year></pub-date><volume>0</volume><issue>18</issue><fpage>61</fpage><lpage>64</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Мещерякова Н.Н., 2017</copyright-statement><copyright-year>2017</copyright-year><copyright-holder xml:lang="ru">Мещерякова Н.Н.</copyright-holder><copyright-holder xml:lang="en">Mescheryakova N.N.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.med-sovet.pro/jour/article/view/2033">https://www.med-sovet.pro/jour/article/view/2033</self-uri><abstract><p>Бронхиальная астма – это хроническое заболевание, а значит, оно будет сопровождать пациента всю его жизнь, и поэтому целью лечения является достижение и поддержание контроля над симптомами БА (GINA 2016). Одним из важных инструментов контроля над состоянием пациентов является использование пикфлоуметров и ведение дневников пикфлоуметрии. В отношении небулайзерной терапии важнейшим аспектом является правильный выбор ситуации применения. В первую очередь этот вид лечения используется в субъективной ситуации потери контроля пациентом над симптомами астмы или по изменившимся показателям пикфлоуметрии.</p><p> </p></abstract><trans-abstract xml:lang="en"><p>Bronchial asthma is a chronic disease and this means that it will accompany the patient all his life and that’s why the aim of treatment is achievement and maintenance of control of BA symptoms (GINA 2016). One of the major control tools over the state of patients is use of peak flow meters and maintenance of peak flowmetry diaries. In respect of the nebulizer therapy the most important aspect is the correct choice of the situation of use. First of all, this type of therapy is used in a subjective situation of the patient control loss over symptoms of asthma or by changed peak flowmetry values.</p><p> </p></trans-abstract><kwd-group xml:lang="ru"><kwd>бронхиальная астма</kwd><kwd>контроль над симптомами</kwd><kwd>пикфлоуметрия</kwd><kwd>небулайзерная терапия</kwd></kwd-group><kwd-group xml:lang="en"><kwd>bronchial asthma</kwd><kwd>symptom control</kwd><kwd>peak flowmetry</kwd><kwd>nebulizer therapy</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Global Strategy for Asthma Management and Prevention. Global Initiative for Asthma (GINA), Updated 2011–2014. www.ginasthma.org.</mixed-citation><mixed-citation xml:lang="en">Global Strategy for Asthma Management and Prevention. Global Initiative for Asthma (GINA), Updated 2011–2014. www.ginasthma.org.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Global Strategy for Asthma Management and Prevention. Global Initiative for Asthma (GINA), Updated 2016. www.ginasthma.org. Accessed July, 8, 2016.</mixed-citation><mixed-citation xml:lang="en">Global Strategy for Asthma Management and Prevention. Global Initiative for Asthma (GINA), Updated 2016. www.ginasthma.org. Accessed July, 8, 2016.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Российское респираторное общество. Федеральные клинические рекомендации по диагностики и лечению бронхиальной астмы. 2016. www. Spulmo.ru</mixed-citation><mixed-citation xml:lang="en">Российское респираторное общество. Федеральные клинические рекомендации по диагностики и лечению бронхиальной астмы. 2016. www. Spulmo.ru</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Авдеев С.Н. Устройства доставки ингаляционных препаратов, используемых при терапии заболеваний дыхательных путей. РМЖ, Пульмонология, аллергология, 2002, 10, 5(149): 255-262.</mixed-citation><mixed-citation xml:lang="en">Авдеев С.Н. Устройства доставки ингаляционных препаратов, используемых при терапии заболеваний дыхательных путей. РМЖ, Пульмонология, аллергология, 2002, 10, 5(149): 255-262.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Hamalainen RM, Kainenk L et al. ERS. Annual Congress 9abs. 1998. Geneve. PO.469.</mixed-citation><mixed-citation xml:lang="en">Hamalainen RM, Kainenk L et al. ERS. Annual Congress 9abs. 1998. Geneve. PO.469.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
